Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

Appleman Leonard J.; Beumer Jan H.; Jiang Yixing; Lin Yan; Ding Fei; Puhalla Shannon; Swartz Leigh; Owonikoko Taofeek K.; Harvey R. Donald; Stoller Ronald; Petro Daniel P.; Tawbi Hussein A.; Argiris Athanassios; Strychor Sandra; Pouquet Marie; Kiesel Brian; Chen Alice P.; Gandara David; Belani Chandra P.; Chu Edward; Ramalingam Suresh S.

首页> 外文期刊>Cancer chemotherapy and pharmacology. >Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

【24h】

Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

机译：Veliparib（ABT-888），聚（ADP-核糖）聚合酶抑制剂的第1期研究，用Carboplatin和Parlitaxel在先进的固体恶性肿瘤中

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose Veliparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP)-1 and -2. PARP-1 expression may be increased in cancer, and this increase confers resistance to cytotoxic agents. We aimed to determine the recommended phase 2 dose (RP2D), maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics (PK) of veliparib combined with paclitaxel and carboplatin.

机译：目的Veliparib是聚（ADP-核糖）聚合酶（PARP）-1和-2的口服抑制剂。 PARP-1表达可能在癌症中增加，这种增加促进对细胞毒剂的抗性。我们的旨在确定推荐的2剂量（RP2D），最大耐受剂量（MTD），剂量限制毒性（DLT）和VELIPARIB的药代动力学（PK）与紫杉醇和卡铂联合。

著录项

来源
《Cancer chemotherapy and pharmacology. 》 |2019年第6期| 共13页
作者
Appleman Leonard J.; Beumer Jan H.; Jiang Yixing; Lin Yan; Ding Fei; Puhalla Shannon; Swartz Leigh; Owonikoko Taofeek K.; Harvey R. Donald; Stoller Ronald; Petro Daniel P.; Tawbi Hussein A.; Argiris Athanassios; Strychor Sandra; Pouquet Marie; Kiesel Brian; Chen Alice P.; Gandara David; Belani Chandra P.; Chu Edward; Ramalingam Suresh S.;
展开▼
作者单位

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Penn State Hershey Canc Inst Hershey PA USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Emory Univ Winship Canc Inst Atlanta GA 30322 USA;

Emory Univ Winship Canc Inst Atlanta GA 30322 USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

NCI Bethesda MD 20892 USA;

Univ Calif Davis Ctr Comprehens Canc Div Hematol &

Oncol Davis CA USA;

Penn State Hershey Canc Inst Hershey PA USA;

Univ Pittsburgh Sch Med UPMC Hillman Canc Ctr Pittsburgh PA 15213 USA;

Emory Univ Winship Canc Inst Atlanta GA 30322 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学 ;
关键词
Veliparib; Poly(ADP-ribose) polymerase; Paclitaxel; Carboplatin; Phase 1; Clinical trial; Advanced cancer;

机译：Veliparib;聚（ADP-核糖）聚合酶;紫杉醇;卡铂;第1阶段;临床试验;晚期癌症;

相似文献

外文文献
中文文献
专利

1. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies [J] . Appleman Leonard J., Beumer Jan H., Jiang Yixing, Cancer chemotherapy and pharmacology. . 2019 ,第6期

机译：Veliparib（ABT-888），聚（ADP-核糖）聚合酶抑制剂的第1期研究，用Carboplatin和Parlitaxel在先进的固体恶性肿瘤中
2. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. [J] . Kummar S, Kinders R, Gutierrez ME, Journal of Clinical Oncology . 2009 ,第16期

机译：聚（ADP-核糖）聚合酶抑制剂ABT-888在晚期恶性肿瘤患者中的0期临床试验。
3. Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells [J] . HsuH.-W., DeNecochea-CampionR., WilliamsV., Oral oncology . 2014 ,第7期

机译：Linifanib（ABT-869）在头颈部癌细胞中使用聚（ADP-核糖）聚合酶抑制剂veliparib（ABT-888）增强细胞毒性
4. DESIGN AND SYNTHESIS OF NOVEL POLY ADP-RIBOSE POLYMERASE 1(PARP1)INHIBITORS FOR THE TREATMENT OF SOLID TUMORS [C] . J.Priyancy, D.P.Bhumika Conference on Drug Design and Discovery Technologies . 2020

机译：用于治疗实体肿瘤的新型聚ADP-核糖聚合酶1（PARP1）抑制剂的设计与合成
5. Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity [D] . Velagapudi, Uday Kiran. 2019

机译：聚（ADP-核糖）聚合酶抑制剂的设计与合成：腺苷袋结合基序附录对3-氧代-2,3-二氢苯并呋喃-7-甲酰胺对效力和选择性的影响
6. Phase I safety pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors [O] . Patricia M. LoRusso, Jing Li, Angelika Burger, -1

机译：聚（ADP-核糖）聚合酶（PARP）抑制剂veliparib（ABT-888）与伊立替康联合治疗晚期实体瘤的I期安全性药代动力学和药效学研究
7. Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies [O] . Kummar, Shivaani, Kinders, Robert, Gutierrez, Martin E., 2009

机译：聚（ADP-核糖）聚合酶抑制剂ABT-888在晚期恶性肿瘤患者中的0期临床试验

Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

摘要

著录项

相似文献

相关主题

期刊订阅